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Myxomatosis is a rapidly lethal disease of European rabbits that is caused by myxoma virus (MYXV). The introduction of a
South American strain of MYXV into the European rabbit population of Australia is the classic case of host-pathogen coevolu-
tion following cross-species transmission. The most virulent strains of MYXV for European rabbits are the Californian viruses,
found in the Pacific states of the United States and the Baja Peninsula, Mexico. The natural host of CalifornianMYXV is the
brush rabbit, Sylvilagus bachmani. We determined the complete sequence of the MSW strain of Californian MYXV and per-
formed a comparative analysis with other MYXV genomes. TheMSW genome is larger than that of the South American Laus-
anne (type) strain of MYXV due to an expansion of the terminal inverted repeats (TIRs) of the genome, with duplication of the
M156R,M154L,M153R,M152R, andM151R genes and part of theM150R gene from the right-hand (RH) end of the genome at
the left-hand (LH) TIR. Despite the extreme virulence of MSW, no novel genes were identified; five genes were disrupted by mul-
tiple indels or mutations to the ATG start codon, including two genes,M008.1L/R andM152R, with major virulence functions in
European rabbits, and a sixth gene,M000.5L/R, was absent. The loss of these gene functions suggests that S. bachmani is a rela-
tively recent host for MYXV and that duplication of virulence genes in the TIRs, gene loss, or sequence variation in other genes
can compensate for the loss ofM008.1L/R andM152R in infections of European rabbits.
The introduction ofMyxoma virus (MYXV), the cause of myx-omatosis, into the European rabbit (Oryctolagus cuniculus)
population of Australia and the subsequent evolution of virus and
rabbit form a classic example of host-pathogen coevolution.
MYXV (family Poxviridae; subfamily Chordopoxvirinae; genus
Leporipoxvirus) originally evolved in the Americas. Two geo-
graphically separated types ofMYXV are known: the South Amer-
ican virus, released as a biological control into European rabbit
populations in Australia and Europe, and the Californian virus,
which is present in the Pacific states of the United States and the
Baja Peninsula, Mexico (1, 2).
Both geographic types ofMYXVnaturally infect leporids of the
genus Sylvilagus: Sylvilagus brasiliensis (tapeti) in South America
and Sylvilagus bachmani (brush rabbit) in California. In its native
hosts, MYXV induces an innocuous cutaneous fibroma at the site
of infection; virus is passively transmitted on the mouthparts of
biting arthropods, such as mosquitoes or fleas, probing through
the virus-rich epidermis of the fibroma for a blood meal. How-
ever, in the European rabbit, which is not native to the Americas,
both types of MYXV induce the lethal generalized disease myxo-
matosis, characterized by a profound suppression of innate and
adaptive host immune responses (3, 4). A third leporipoxvirus,
calledRabbit fibroma virus (RFV; also called Shope fibroma virus),
is found in Sylvilagus floridanus (eastern cottontail) in the eastern
and central states of the United States and Ontario, Canada. RFV
does not cause significant disease in immunocompetent European
rabbits but genetically and antigenically is sufficiently closely re-
lated to MYXV to be used as a heterologous vaccine against myx-
omatosis. Each virus appears to be well adapted to its natural host,
based on transmission studies and the lack of serious disease (1, 5,
6), and it has been assumed that this indicates a long period of
host-pathogen coevolution quite distinct from the rapid emer-
gence and host adaptation of South American strains of MYXV in
the novel European rabbit host inAustralia andEurope (1, 3, 7–9).
Myxomatosis in California was first described for farmed Eu-
ropean rabbits in the 1930s (10). Fenner and Marshall (11) char-
acterized two isolates of Californian MYXV: MSD (San Diego
1949) andMSW (San Francisco 1950). Similar to South American
strains of MYXV, these viruses were highly lethal in European
rabbits, with case fatality rates of essentially 100%, but most in-
fected rabbits died before developing the classic swollen head,
ears, eyelids, and perineum of myxomatosis. In addition, high
titers of virus were found in the brains of infected rabbits, and
some rabbits exhibited neurological signs such as convulsions (1).
Thus, the Californian viruses were considered to be neurotropic.
Subsequent studies with MSW have confirmed the extreme viru-
lence of the virus for European rabbits, both fully susceptible lab-
oratory rabbits and Australian wild rabbits with genetic resistance
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toMYXV (12). However, in these studies, high titers of virus were
not found in the brain.
The complete nucleotide sequences of the Lausanne (Lu) strain
of South AmericanMYXV and the Kazza strain of RFV have been
described previously (13–15). The Lu genome consists of 161,777
bp of double-stranded DNA (dsDNA) with terminal inverted re-
peats (TIRs) of 11,577 bp and closed single-stranded hairpin loops
at each terminus. There are 158 unique open reading frames
(ORFs), 12 of which are duplicated in the TIRs. RFV has a genome
of 159,857 bp carrying 151 unique genes, 12 of which are dupli-
cated or partly duplicated in the 12,397-bp TIRs. Orthologues of
all theRFVgenes are present in equivalent positions inMYXV, but
sevenORFs inMYXV are present only as fragments or aremissing
in RFV.
Both the Lu and RFV genomes encode multiple proteins in-
volved in host range determination and suppression or evasion of
host innate and adaptive immune responses (3, 4). In their natural
hosts, these proteins are presumed to be essential for virus persis-
tence at high titers and enable sufficient time for vector transmis-
sion; persistence in RFV can be more than 9 months, allowing
overwintering in the absence of vectors. However, in European
rabbits, MYXV completely overwhelms the host response. Gene
knockout studies of Lu have implicated at least 21MYXV genes in
virulence for laboratory rabbits, and another 20 genes have poten-
tial or confirmed immune evasion or host range functions, some
of which likely affect virulence (3). Only limited sequence map-
ping of Californian MYXV has been undertaken to date. This
demonstrated that a number of potential virulence genes were
duplicated in the MSW and MSD strains, by an expansion of the
TIRs compared to those in Lu. However, no novel genes were
identified that could explain the very high virulence of Californian
viruses (16). Here we describe the complete genome sequence of
the MSW strain of Californian MYXV. A comparative analysis
with other MYXV genomes provides a new opportunity to exam-
ine the adaptation of the leporipoxviruses to their natural hosts, as
well as the mechanisms of MYXV virulence in European rabbits.
MATERIALS AND METHODS
Virus and DNA preparation.MSW:myxoma virus:California/San Fran-
cisco 1950 (11) was originally obtained as freeze-dried powdered rabbit
tissue from the late Frank Fenner (John Curtin School of Medical Re-
search, Australian National University, Canberra, Australia). The virus
was subsequently passaged once in a laboratory rabbit, and testis-derived
virus was amplified three times in RK-13 cells to generate seed and work-
ing stocks. The third-passage working stock was used to infect 10 T175
flasks of RK-13 cells at a multiplicity of infection (MOI) of approximately
0.075, and virus DNA was prepared as previously described (9).
Sequencing and assembly.Template viral DNAwas processed using a
TruSeq DNA sample preparation kit (Illumina) to produce a multiplex
library for sequencing. Briefly, extracted viral genomic DNA (gDNA) was
sheared with a Covaris AFA system, creating fragments of 50 to 7,000 bp;
sheared samples were then end repaired, purified, and 3= adenylated. Bar-
coded sequencing adapters were ligated, and 400- to 500-bp fragments
were purified. After fragment enrichment and cleanup with AMPure XP
beads, individual library components were quantitated by quantitative
PCR (qPCR), normalized, and pooled into a final sequencing library con-
sisting of 8 different viral genomes (this included seven other SouthAmer-
icanMYXV strains that were analyzed in a separate study), which was run
in a single lane of an Illumina HiSeq2000 to generate 100-bp paired-end
reads. De-multiplexed reads were quality trimmed with the trim.pl script
(http://wiki.bioinformatics.ucdavis.edu/index.php/Trim.pl) and assem-
bled with the Velvet de novo assembler (17), using a k-mer value of 61 and
an expected coverage of 2,000. A single scaffold consisting of two contigs
was generated, with homogeneous coverage across the single copy region
of the segment. A 28-bp gap between the two contigs was closed by PCR.
Only one complete, or nearly complete, copy of the TIR was assembled at
either the 5= or the 3= end, though up to a full read length of the comple-
mentary TIR was observed at the opposite end, allowing easy identifica-
tion of theTIR junction. To further verify the position of theTIR junction,
we duplicated the complete TIR, generated a reverse complement of the
sequence that was added on the opposite end, and remapped the sequence
reads to that assembled portion of the genome. A subset of 2,000,000 reads
was then mapped to the assembly with the added TIR sequence, and the
junction of the TIR was inspected for both read pairs that spanned this
region, as well as reads in either direction spanning the TIR junction.
Data analysis. Genome annotation was transferred from Lu to MSW
by use of the Rapid Annotation Transfer Tool (18) and from previous
genome mapping of the partial sequence of MSW (16). EMBL flat files of
transferred gene models were then inspected and compared to the Lu
reference by using the Artemis comparison tool (19); models were cor-
rected, and new genemodels were addedwhere transfer had not occurred.
Artemis was used to write out multi-fasta nucleotide-containing entries
for each gene from all analyzed genomes. Gene IDs were added based on
the location in the MYXV genome, with the direction of transcription
indicated by L or R (e.g., M010L). Genes in the TIR are identified by L/R
(e.g., M007L/R). Proteins are identified by the same number as the gene,
with the transcription direction omitted (e.g., M010). RFV genes and
proteins are prefixed with S rather than M, and the numbering system is
syntenic with that of Lu, apart from the duplication caused by the ex-
panded TIR in RFV, such that the S008.2L/R gene is equivalent toM156R
and the S155R gene is a truncated form of S009L (15). Amino acid se-
quences for all MSWORFs were aligned with the orthologous amino acid
sequences of Lu (accession number NC_001132) and RFV (accession
number AF170722), using Clustal implemented in Bioedit (20); align-
ments were manually adjusted and percent identity calculated in Bioedit.
The uncorrected genetic distance (P distance) between Lu and MSW was
estimated using MEGA v5 (21).
Analysis of the MSW and SG33 recombinant sequences. The SG33
vaccine strain of MYXV was derived from a French field strain (itself
derived from the South American Lausanne strain), but at some stage
SG33 or its progenitor recombined with a Californian strain of MYXV
[possibly the vaccine derived from theMSD(SanDiego 1949) strain] (22).
We used the RDP, GENECOV, and Bootscan methods available in the
RPD3 package (23; http://darwin.uvigo.es/rdp/rdp.html) to characterize
the recombination breakpoints in SG33 compared to the complete ge-
nome sequences of MYXV strains MSW, Lu, and SLS and RFV. Default
parameters were used in all cases. Phylogenetic trees for each recombinant
region detected in the RPD3 analysis (see Results) were then inferred
using the maximum likelihood (ML) method available in the PhyML
package (version 3.0) (24), and assuming a GTRmodel of nucleotide
substitution, subtree pruning and regrafting (SPR) branch swapping, and
1,000 bootstrap replications.
For an additional fine-scale screen for recombination breakpoints be-
tween sites 78,000 and 83,000 (seeResults), we employed a slidingwindow
Bayesian Markov chain Monte Carlo (MCMC) approach. For this analy-
sis, MrBayes trees (25) were generated for 100-bp windows (with a step
size of 10 bp), using four chains and 120,000 MCMC generations, with
sampling every 50 generations and with five burn-in samples removed.
Posterior probabilities for both the SG33/MSWand SG33/LuSLS topol-
ogies were then plotted in R, using the GGplot2 library.
Nucleotide sequence accession numbers. Sequence data generated in
this study have been submitted to GenBank and assigned accession num-
ber KF148065.
RESULTS
The MSW genome consists of 164,600 bp of dsDNA with an AT
content of 54.56% (compared to 56.4% for Lu and 60.5% for
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RFV). This genome is larger than that of Lu (161,777 bp), pre-
dominantly due to an expansion of the TIRs (see below). Aside
from the TIR expansion, the gene orders in MSW and Lu are
identical, with the exception thatMSW lacks theM000.5L/RORFs
at the extreme ends of the TIRs. There are at least 19,182 (ob-
served) nucleotide substitutions in MSW compared to Lu (P dis-
tance of 0.12). Based on the Lu sequence, MSW carries 152 intact
genes, 15 of which—plus two disrupted ORFs—are duplicated or
partially duplicated in the TIRs. In addition, five ORFs present in
Lu are disrupted by indels or mutations to the ATG start codon in
MSW. Table 1 summarizes the MSW genes and compares the
amino acid sequence of each protein with those of its orthologues
from Lu and RFV. No novel genes were identified in the MSW
sequence compared to Lu.
TIR expansion. The TIRs of MSW consist of 15,464 bp each,
compared to 11,577 bp in Lu; each TIR incorporates orthologues
of the LuM001L/R,M002L/R,M003.1L/R,M003.2L/R,M004L/R,
M004.1L/R, M005L/R, M006L/R, M007L/R, M008L/R, M156R,
M154L,M153R, andM151R genes and the 3= 694 bp of theM150R
gene. Sequences orthologous to the Lu M008.1L/R (SERP-1) and
M152R (SERP-3) ORFs are present in the MSW TIR but have
multiple disruptions to theORFs (see below). Compared to the Lu
TIR, 4,216 bp of theM156R,M154L,M153R,M152R, andM151R
sequences and part of the M150R sequence from the right-hand
(RH) end of the genome have been duplicated at the left-hand
(LH) TIR. This duplication has been accompanied by the deletion
of 845 nucleotides (nt) of the 3= end of theM009L gene (based on
the Lu sequence) and the 23-nt untranslated sequence between the
stop codon of M009L and the TIR boundary (Fig. 1). The pro-
moter and 5= 782 bp of theM150R gene have not been duplicated,
so the TIR boundary now occurs at this point in M150R rather
than in theM156R gene, as in Lu, or theM009L gene, as in RFV. A
full-length copy of theM150R gene ismaintained at the RH end of
the genome.
Genes disrupted or missing in MSW. Compared to Lu, the
following genes are disrupted or missing in MSW. The Lu
M000.5L/R gene is a predicted ORF encoding 72 amino acids (aa)
at the extreme ends of the genome and has an unknown function
(13). It is not known if this is a functional gene, and there are no
homologues of the putative protein inGenBank. Although there is
anATG codon inMSWat the same location as that of the LuATG,
there is noORF and there aremultiple large gaps in the alignment.
The Lu M008.1L/R gene is the final complete ORF in the
Lu TIR, and it encodes a secreted serine proteinase inhibitor
(SERP-1) of 369 aa which inhibits the inflammatory response and
has a major role in virulence (26, 27). The equivalent nucleotide
sequence in MSW retains an ATG start codon and TAA stop
codon in equivalent positions, but multiple indels disrupt the
ORF. There is a potential ORF encoding 204 aa, starting at the
ATG at position 409, with an imperfect late promoter sequence
(CCAAAATG; italics indicate A rather than the consensus T at
1, and underlining indicates 1 to 4 of the putative pro-
moter). The translated ORF aligns with aa 142 to 268 of Lu
M008.1, but after aa 268 the sequence homology is lost.
The Lu M009L gene encodes a putative E3 ubiquitin (Ub) li-
gase of 509 aawith anN-terminal BTB-BACKdomain followed by
4 kelch motifs (28). The MSW M009L sequence aligns with only
the first 685 nucleotides of the Lu sequence; after this, the next 845
nt of M009L have been replaced by a sequence from the RH end
due to the expansion of the TIR at the LH end of the genome (see
above). The ORF, however, encodes only the first 96 aa of M009
due to a stop codon and multiple indels after this point. Most
recent Australian isolates of MYXV have a disruption to the
M009L ORF (9), which suggests that M009L is not important for
MYXV in eitherO. cuniculus or S. bachmani. LuM023R encodes a
61-aa protein of unknown function. However, in MSW, the ATG
start codon is mutated to ACG, which also mutates the critical T
residue at position4 in the late promoter structure to a C (from
AGTAAATG in Lu to AGTAAACG in MSW; the promoter from
positions 3 to 4 is underlined). Transcription would be pre-
dicted to initiate at the A at position 1 (shown in italics), and
translation starts at the ATG. In addition, there is a CC insertion at
nt 83 and 84, which would disrupt the MSW ORF. An in-frame
ATG at nt 19 in Lu is also present in theMSW sequence andwould
provide a potential ORF encoding 32 aa in MSW, with only 12
amino acids aligning with the Lu sequence. The RFV orthologue,
S023R, encodes a potential 35-aa proteinwhich is 74% identical to
the N-terminal 35-aa sequence of the Lu M023 protein.
M131R encodes an inactive homologue of mammalian
Zn/Cu superoxide dismutase (SOD) and is predicted to inter-
fere with the activity of cellular SOD (29–31). Deletion of the
M131R gene had no effect on the virulence of MYXV in Euro-
pean rabbits. The MSW M131R ORF is disrupted by multiple
in-frame stop codons.
Finally, LuM152R encodes the 266-aa SERP-3 protein, which is a
virulence factor inEuropean rabbits (32).TheMSWM152Rortholo-
gous sequence contains multiple stops in all reading frames.
Genes with major differences between Lu and MSW. Lu
M013L encodes a 126-aa polypeptide with a pyrin (PYD) domain
in the N-terminal 81 aa (33, 34). The MSWM013 protein is only
112 aa due to a deletion after residue 87, but the PYD domain is
highly conserved with both Lu and RFV, which has a similar de-
letion after residue 83 and carries a full-length protein of 107 aa.
The LF residues at the C terminus are also conserved in the virus
proteins, including that of MSW, but are not present in the PYD
domains in the cell proteins POP and ASC (33).
Note that MSW lacks the C-terminal 9 residues of M030L
(RNA polymerase subunit rpo30; intermediate transcription
factor 1) compared to RFV and Lu. Lu M063R encodes a host
range protein which is required for replication in rabbit cells
and European rabbits but is not necessary for replication in
primate cell lines (35). The protein has sequence homology to
the vaccinia virus (VACV) host range C7 protein and also to the
proteins encoded byM062R andM063R. The MSW orthologue
has relatively limited amino acid sequence homology to both
M063 of Lu (67.9% identity) and SO63 of RFV (64.3% iden-
tity). Like that of RFV, it lacks 9 aa from the highly acidic
C-terminal region of M063, with a predicted protein of 201 aa,
compared to 215 aa in Lu and 202 aa in RFV. Despite the
sequence divergence, all three proteins are compatible with
replication in European rabbits.
Lu M077L encodes a 143-aa structural protein orthologous to
VACV D2. The MSW M077 protein is potentially 23 aa longer at
the N terminus due to an alternative in-frame ATG within the
M078RORF. D2 forms part of a seven-protein core complex dur-
ing VACV assembly (36). Interestingly, the MYXV vaccine strain
SG33 has the same sequence as MSW for this gene following a
recombination event (see below).
M119L encodes a small polypeptide (50 aa) of unknown func-
tion. BothMSW and RFV carry smaller potential ORFs, encoding
Kerr et al.
12082 jvi.asm.org Journal of Virology
 o
n
 M
arch 12, 2015 by Australian National Univ.
http://jvi.asm.org/
D
ow
nloaded from
 
TABLE 1 Summary of MSW genes and functions and comparison of amino acid sequences with those of orthologues in Lu and RFV
Gene Location (nt) Function of gene product
No. of aa
% Identity to
Lu protein No. of RFV aa
% Identity to
RFV proteinMSW Lu
M000.5L Not present Unknown 72 NAa
M001L 592–1353 Secreted chemokine binding protein 253 260 68.8 258 70.9
M002L 1456–2424 Tumor necrosis factor receptor (TNF-R) homologue 322 326 73.3 325 77.2
M003.1L 2531–2986 VACV B15R 151 151 84.7 151 77.4
M003.2L 3056–3400 Unknown 114 113 80.8 125 79.3
M004L 3629–4342 Apoptosis regulator 237 237 78 225 70
M004.1L 4346–4615 Unknown 89 90 91.1 80 80.8
M005L 4635–6086 E3 Ub ligase 483 483 83.6 484 74.1
M006L 6120–7649 Putative E3 Ub ligase 509 509 77 508 73.4
M007L 7690–8478 Gamma IFN receptor homologue 262 263 83.6 262 69
M008L 8526–10079 Putative E3 Ub ligase 517 515 77.9 514 70.2
M008.1L Disrupted Secreted serpin 369 Deleted
M156L 11134–11367 Interferon resistance; elF2 homologue Not present in this
location
Not present in this
location
M154R 11578–12219 Downregulation of NF-B? VACVM2L orthologue Not present in this
location
Not present in this
location
M153L 12312–12917 E3 Ub ligase/major histocompatibility complex class
1 (MHC-1) downregulation
Not present in this
location
Not present in this
location
M152L Disrupted SERP-3 Not present in this
location
Not present in this
location
M151L 13754–14755 SERP-2 Not present in this
location
Not present in this
location
M150L Partial sequence
(14771–15464)
Not present in this
location
Not present in this
location
M009L Truncated sequence
(15465–16151)
Putative E3 Ub ligase 509 510
M010L 16519–16770 Epidermal growth factor-like protein 83 85 83.5 80 69
M011L 16752–17252 Apoptosis regulator 166 166 71.8 163 74.6
M012L 17268–17717 dUTP nucleotidylhydrolase 149 148 87.2 143 82
M013L 17736–18074 Pyrin domain/inflammasome 112 126 62.5 107 74.1
M014L 18104–19657 Putative E3 Ub ligase 517 517 84.5 516 77.2
M015L 19708–20676 Ribonucleotide reductase small subunit 322 322 95.6 322 94.4
M016L 20705–20938 Unknown 77 77 67.5 82 53.6
M017L 20941–21171 Unknown 76 76 86.8 77 81.8
M018L 21386–21586 VACV F8L 66 66 96.9 66 96.9
M019L 21641–22288 Fusion/entry 215 215 96.2 215 93.4
M020L 22266–23606 Ser/Thr protein kinase 446 446 95.5 445 93.2
M021L 23733–25610 Enveloped virus (EV) maturation 625 625 88.3 627 84.2
M022L 25642–26757 EV protein 371 371 94.8 370 93.5
M023L Disrupted Unknown 61 35
M024L 26928–27374 VACV F15L 148 148 95.2 148 94.5
M025L 27431–28060 VACV F16L 209 209 93.3 209 89.9
M026R 28101–28409 DNA binding 102 102 97 101 88.3
M027L 28406–29818 Poly(A) polymerase (Pol) catalytic subunit 470 470 98.2 470 97.2
M028L 29815–32010 EV formation? 731 731 88.9 721 85.5
M029L 32050–32397 IFN resistance; VACV E3L orthologue 115 115 88.6 116 85.3
M030L 32460–33107 RNA Pol subunit 215 222 86.1 222 83.4
M031R 33208–34392 Virosome protein 394 393 77.4 392 75.8
M032R 34402–36099 VACV E6R 565 565 95.9 565 92.2
M033R 36102–36920 Core protein 272 272 97.7 274 94.8
M034L 36917–39940 DNA Pol 1007 1006 96.2 1005 92.1
M035R 39974–40264 Thiol-oxidoreductase 96 96 90.6 96 89.5
M036L 40285–42327 VACV O1L/Erk1/2 signaling? 680 680 91.3 681 88.1
M037L 42363–42461 VACV 03L/fusion complex 32 32 100 32 93.7
M038L 42472–43413 Core protein 313 313 95.2 313 94.5
M039L 43414–43638 VACV I2L/membrane protein 74 74 83.7 74 89.1
M040L 43639–44448 DNA binding protein 269 270 95.9 270 93.7
M041L 44522–44758 Structural protein 78 78 96.1 78 83.3
M042L 44779–45939 Core protein 386 386 92.2 386 91.1
M043L 45932–47221 Core protein 429 429 97.6 429 96.2
M044R 42227–49263 RNA helicase/nucleophosphohydrolase 678 678 90.7 678 88
M045L 49260–51032 Core enzyme 590 590 90.3 590 86.4
M046L 51029–51364 Fusion/entry 111 111 94.5 111 94.5
M047R 51358–52035 Elongation factor/late transcription 225 225 92.8 225 91.1
M048L 51993–52382 Glutaredoxin 2 homologue 129 128 96.1 128 95.3
M049R 52385–53680 Core protein 431 431 85.3 432 84
M050R 53682–53873 RNA Pol subunit 63 63 93.6 63 96.8
M051R 53873–54394 VACV G6R 173 174 93.6 174 89.6
M052L 54363–55415 Core protein 350 350 94.2 350 90.5
M053R 55445–56227 Late transactivator protein 260 260 98.8 260 99.2
M054R 56247–57245 Fusion complex 332 332 93.9 332 92.7
M055R 57246–57974 Structural protein 242 242 99.1 242 97.1
M056R 58030–58329 VACV L2R 99 99 61.6 99 66.6
(Continued on following page)
Genome Sequence of Myxoma Virus Californian MSW Strain
November 2013 Volume 87 Number 22 jvi.asm.org 12083
 o
n
 M
arch 12, 2015 by Australian National Univ.
http://jvi.asm.org/
D
ow
nloaded from
 
TABLE 1 (Continued)
Gene Location (nt) Function of gene product
No. of aa
% Identity to
Lu protein No. of RFV aa
% Identity to
RFV proteinMSW Lu
M057L 58279–59241 Core protein 320 320 91.8 320 92.8
M058R 59266–60021 Major core protein 251 251 97.6 251 97.2
M059R 60040–60429 Fusion/entry 129 129 98.4 129 94.5
M060R 60383–60829 Structural protein 148 148 93.9 148 90.5
M061R 60860–61396 Thymidine kinase 178 178 89.8 178 83.7
M062R 61474–61947 Host range protein 157 158 83.5 158 74.6
M063R 62004–62609 Host range protein 201 215 67.9 202 64.3
M064R 62655–63254 Host range protein 199 203 76.5 198 64.1
M065R 63296–64312 Poly(A) Pol subunit 338 338 98.5 338 96.4
M066R 64212–64769 RNA Pol subunit 185 185 97.2 185 93.5
M067L 64772–65173 Fusion complex 133 133 98.4 133 95.4
M068R 65247–69107 RNA Pol subunit 1286 1286 97.8 1286 97.9
M069L 69115–69633 Tyr/Ser phosphatase 172 172 98.8 173 95.3
M070R 69649–70221 Fusion complex 190 190 98.4 190 97.3
M071L 70224–71198 Structural protein 324 324 94.4 324 89.1
M072L 71199–73589 RNA Pol-associated transcription factor 796 796 95.4 798 95.1
M073R 73719–74303 Late transactivator protein 194 194 88.7 198 82.4
M074R 74331–75278 DNA topoisomerase 1 315 315 94.9 314 95.8
M075R 75278–75721 VACV H7R 147 147 95.9 150 89.3
M076R 75723–78230 mRNA capping enzyme subunit 835 835 93.2 836 91.8
M077L 78192–78692 Structural protein 166 166 80.7 166 72.2
M078R 78629–79351 Structural protein 240 240 91.2 241 82.9
M079R 79348–80004 Uracil-DNA glycosylase 218 218 96.7 218 94.9
M080R 80038–82398 Nucleoside triphosphatase 786 786 97.3 786 96
M081R 82395–84302 Early transcription factor subunit 635 635 97.9 635 97.9
M082R 84335–84826 RNA Pol subunit 163 163 95 163 95.7
M083L 84797–85654 Carbonic anhydrase homologue/structural protein? 285 286 90.5 285 87.3
M084R 85703–86323 VACV D9R/MutT-like protein 206 206 91.7 206 93.2
M085R 86320–87099 VACV D10R/MutT-like protein 259 259 88.4 260 88.8
M086L 87102–89000 Nucleoside triphosphatase 1/DNA helicase 632 632 93.9 632 92.5
M087L 89018–89881 mRNA capping enzyme, small subunit/VITF 287 287 97.9 287 97.2
M088L 89910–91571 Intracellular mature virion (IMV) virion protein 553 554 96 552 94.3
M089L 91598–92047 Late transcription factor 2 149 149 93.9 149 94.6
M090L 92081–92755 Late transcription factor 3 224 224 99.1 224 99.1
M091L 92752–92979 Thiol oxido reductase 75 75 98.6 75 94.6
M092L 92988–94946 Core protein 652 653 96.9 653 94.6
M093L 94984–95454 Core protein 156 159 79.8 153 69.2
M094R 95494–95988 RNA Pol subunit 164 164 97.5 164 95.1
M095L 95985–97106 Core protein 373 373 93.2 373 94.1
M096L 97134–99269 Early transcription factor subunit 711 711 96.4 711 95.7
M097R 99322–100182 Intermediate transcription factor subunit 286 286 95.1 286 93.3
M098L 100183–100416 Membrane protein 77 76 96.1 77 94.8
M099L 100417–103122 Core protein precursor 901 901 93.5 902 90.1
M100R 103137–104078 Scaffolding protein 313 313 95.8 314 95.5
M101L 104075–104563 Virion protein 162 161 93.2 156 88.8
M102L 104596–104802 IMV membrane protein 68 68 91.1 68 77.9
M103L 104856–105149 IMV membrane protein 97 96 95.8 95 91.7
M104L 105166–105327 Potential immunomodulatory protein? 53 53 96.2 53 92.4
M105L 105317–105601 Core protein 94 94 94.6 94 91.4
M106L 105585–106715 Fusion complex 376 376 93.3 376 92.8
M107L 106731–107339 IMV membrane protein 202 200 87.6 199 81.1
M108R 107354–108790 DNA helicase/negative transcriptional regulator 478 478 93 478 91
M109L 108771–108992 VACV A19L 73 73 95.8 73 94.5
M110L 108993–109334 Core protein 113 113 95.5 113 89.3
M111R 109333–110628 DNA Pol 431 431 91.6 432 86.1
M112R 110591–111094 Holliday junction resolvase 167 164 85.9 160 82.6
M113R 111101–112255 Intermediate transcription factor subunit 384 385 95 385 93.5
M114R 112281–115748 RNA Pol subunit 1155 1155 98.2 1155 97.1
M115L 115749–116330 Fusion protein/EV formation/IMV surface protein 193 188 73.2 179 75.7
M116L 116331–116753 IMV membrane protein 140 140 100 140 94.2
M117L 116759–117667 RNA Pol subunit 302 302 94 302 92.3
M118L 117636–117866 Core protein 76 76 94.7 76 93.3
M119L 117882–118004 Unknown 40 50 65 39 65
M120L 118038–118805 ATPase 255 255 97.2 255 96.4
M121R 118890–119420 EV glycoprotein/NK receptor homologue 176 176 81.2 172 75
M122R 119427–119942 EV glycoprotein/NK receptor homologue 171 172 94.7 171 91.8
M123R 119976–120515 VACV A35R 179 179 88.8 179 85.4
M124R 120551–121411 Unknown 286 286 86.7 286 87.4
M125R 121425–121928 Unknown 167 161 81.4 164 70.1
M126R 121970–122785 VACV A37R/structural protein? 271 271 92.2 271 88.1
M127L 122772–124109 Photolyase 445 445 88.3 445 84.7
M128L 124112–124960 CD47 homologue 282 281 86.8 290 73.2
M129R 124959–125369 VACV E7R 136 136 88.9 78 46.3
(Continued on following page)
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40 and 39 residues, respectively, that are truncated at the N termi-
nus compared to that in Lu due to initiating at an ATG 30 nucle-
otides downstream of theM119L ATG.
M156R is an orthologue of the VACVK3L gene. Like K3,M156
is phosphorylated by cellular protein kinase R (PKR) and is pre-
dicted to compete with eIF2 for phosphorylation by PKR, thus
inhibiting translational shutdown in response to type 1 interferon
(IFN) (37). MSW M156 and the orthologue in RFV, S008.2, lack
the first 27 aa of the Lu sequence, initiating from a downstream
ATG compared to the case in Lu. This extended N-terminal se-
quence in Lu is also not present in the orthopoxvirus orthologues
of M156, such as K3L. All the other critical binding residues are
conserved between Lu and MSW; Y54, which is conserved be-
tween Lu, the orthopoxviruses, and swinepox virus, is an H in
TABLE 1 (Continued)
Gene Location (nt) Function of gene product
No. of aa
% Identity to
Lu protein No. of RFV aa
% Identity to
RFV proteinMSW Lu
M130R 125440–125823 Unknown 127 122 77.9 104 71.6
M131R Disrupted Cu/Zn superoxide dismutase homologue 163 163
M132L 126359–126892 Unknown 177 175 85.8 175 82.5
M133R 126974–128653 DNA ligase 559 563 91.4 559 89.6
M134R 128772–134765 Variola virus B22R orthologue 1997 2000 85 1939 81.5
M135R 134768–135313 Immunomodulatory protein 181 178 74.5 Deleted
M136R 135496–136041 Homologue of VACV A52; Bcl-2-like fold 181 179 83.9 Deleted
M137R 136042–136974 VACV A51R 310 310 84.5 218 52.2
M138L 137003–137875 Alpha-2,3 sialyltransferase 290 290 81.3 290 81.3
M139R 137926–138492 Homologue of VACV A52; Bcl-2-like fold 188 188 93 Deleted
M140R 138495–140156 Putative E3 Ub ligase 553 553 87.1 553 82.4
M141R 140197–140874 OX-2 homologue 225 218 75.7 223 67
M142R 140882–141814 Ser/Thr protein kinase 310 306 91.6 306 90.3
M143R 141815–142519 RING-E3 Ub ligase 234 234 94.8 234 90.5
M144R 142566–143462 VACV B5R 298 300 76.6 299 75
M146R 143486–143812 VACV N1L orthologue/Bcl-2-like fold 108 108 84.2 108 84.2
M147R 143863–144726 Ser/Thr protein kinase 287 288 88.8 287 86.4
M148R 144792–146816 Putative E3 Ub ligase 674 675 67.6 673 80.4
M149R 146818–148290 Putative E3 Ub ligase 490 490 87.1 490 83.4
M150R 148355–149830 E3 Ub ligase; NF-B inhibition 491 493 78.5 Deleted
M151R 149846–150847 SERP-2 333 333 86.1 333 81.6
M152R Disrupted SERP-3 266 Deleted
M153R 151684–152289 E3 Ub ligase/MHC-1 downregulation 201 206 63.5 201 61.8
M154L 152382–153023 Downregulation of NF-B? VACVM2L orthologue 213 214 89.2 214 84.1
M156R 153234–153467 Interferon resistance; elF2 homologue 77 102 53.3 78 65.3
a NA, not applicable.
FIG 1 Expansion of the TIR regions of MSW compared to Lu. The diagram shows a representation of the gene order around the TIR boundary at the LH and
RHends of the genome for Lu compared to the same regions forMSW.The vertical arrows indicate the TIR junctions.Note thatM008.1L/R is labeled in theMSW
diagram for clarity but that it is not present as an ORF inMSW and hence is depicted as a dashed line rather than an arrow. TheM152L/R sequence also does not
comprise an ORF inMSW and is shown as a dashed line betweenM151L/R andM153L/R but not labeled. The designationsM150L andM009L represent the
truncated forms of these ORFs in MSW.M155 was not used in the MYXV annotation. The figure is not drawn to scale.
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MSW.As noted above, due to the expansion of the TIRs,M156R is
duplicated in MSW.
The promoter usage predicted for Lu and RFV is also interest-
ing, with Lu M156R predicted to be under the control of a late
promoter, albeit one lacking the upstream T/A-rich region, and
rabbit fibroma virus S008.2L/R predicted to be an early gene (13,
15). The upstream sequence for MSW and RFV and the N-termi-
nal Lu coding sequence are shown in Fig. 2. The sequence around
the late promoter is conserved between Lu and MSW, but MSW
has an A instead of a G (Lu sequence, CGTAAATG; and MSW
sequence, CGTAAATA) and no downstream ATG for another 84
nt. It seems likely thatMSWM156R is also an early gene, although
there is a late promotermotif (AGTAAATA) 19 nt upstreamof the
ATG. Systematic mutational analysis of poxvirus early promoter
sequences showed that inclusion of late promoter motifs could
lead to late transcription under some circumstances (38), so it is
possible that this gene is expressed constitutively. A TAAATmotif
is also present 29 nt upstream of the RFV ATG (Fig. 2). Interest-
ingly, Lu, RFV, andMSW all have an early transcription termina-
tion signal (T5NT) at the 3= end of the gene. It would seem logical
for proteins inhibiting type 1 IFN action to be expressed early, as
are the M029L gene and VACV K3L. Since the sequences of the
potential early promoter region upstream of the MSW ATG start
codon are identical between MSW and Lu (Fig. 2), it is possible
that two transcripts are being produced in Lu: an early transcript
that lacks the N-terminal 27 aa, which are not predicted to con-
tribute to the -barrel structure of M156 (37), and a potential
longer late transcript.
Relationship of MSW to the recombinant French SG33 vac-
cine strain of MYXV. MSW has genomic regions exhibiting
strong sequence similarity with the SG33 vaccine strain ofMYXV,
derived from a French field strain by repeated passages in rabbit
kidney cells and chicken embryo fibroblasts (39). The resulting
virus (SG33) appears to have recombinedwith aCalifornian virus,
probably the attenuated vaccine strain derived from MSD (40,
41). This recombinant has a 13.5-kb deletion at the RH end of the
genome encompassing multiple genes associated with virulence
and significantly truncating the TIRs (22).
Using a variety of methods, we detected significant (P	 0.05)
recombination breakpoints at nucleotides 78413, 81576, and
136691 in our genome sequence alignment, such that the com-
plete genome alignment of Lu, MSW, SG33, SLS, and RFV could
be divided into four distinct regions with differing evolutionary
histories (Fig. 3). For regions (nt) 1 to 78412 and 81576 to 136690,
which comprise the majority of the genome, SG33 appears to be a
close sister group of the Lu and SLS strains of MYXV, originally
sampled in South America. In contrast, SG33 is more closely re-
lated (and with strong bootstrap support) to MSW in genomic
regions 78413 to 81575 and 136691 to 168149, such that SG33 is
clearly a recombinant of Californian and South American myx-
oma viruses, although with multiple breakpoints. RFV was the
most divergent lineage, and hence can be assumed to represent an
outgroup. A sliding Bayes analysis within the central genomic re-
gion (nt 77,000 to 83,000) (Fig. 4) revealed a number of highly
localized recombination events between MSW and SG33. Inter-
estingly, the genes located in this region of microrecombination
(M076R,M077L,M078R,M079R, andM080R) have not been dis-
FIG 2 Promoter structure and upstream untranslated regions ofM156R genes fromMSW, Lu, and RFV. The nucleotide sequences immediately upstream of the
M156R, MSWM156R, and RFV S008.2R genes are shown. The postulated Lu start codon at position 150,001 is shown in italics, while the potential late promoter
sequence incorporating this ATG is in a box. The ATG for MSW and RFV and the potential downstream ATG for Lu are shown in bold at the 3= ends of the
sequences. The potential early promoter sequences are underlined, and the TAAATmotifs proximal to these sequences are highlighted by boxes. TheN-terminal
amino acid sequence of the Lu protein is shown under the nucleotide sequence. The RFV sequence upstream of S008.1R is considerably diverged, and no attempt
was made to align it with the Lu and MSW sequences.
FIG 3 Recombination in the evolutionary history of MYXV. Separate ML
trees were estimated for multiple-sequence alignment of regions 1 to 78412
(a), 78413 to 81575 (b), 81576 to 136690 (c), and 136691 to 168149 (d), and the
locations of the recombination breakpoints identified in the RDP3 analysis are
denoted. In all cases, bootstrap support values are shown for key nodes, and all
horizontal branch lengths are scaled according to the number of nucleotide
substitutions per site.
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rupted. Why most recombination events are limited to this 5-kb
region is currently unknown. In addition, it is both notable and
puzzling that Lu and SLS form a sister group to the exclusion of
SG33, even though SG33 was derived from Lu.Whether this is the
result of additional highly localized recombination or selective
events is unclear and merits further investigation. A similarly
complex laboratory recombination event occurred between RFV
and a South American MYXV to form malignant rabbit virus
(MRV) (42, 43).
DISCUSSION
Our analysis of the complete genome sequence of theMSW strain
of Californian MYXV reveals that it is more closely related to the
South AmericanMYXV than is the leporipoxvirus RFV and that it
acts as a parental strain in a recombination event involving the
SG33 vaccine strain ofMYXV.However, despite this phylogenetic
association, no novel genes were identified that could explain the
high virulence of Californian viruses in European rabbits. Indeed,
MSWhas fiveORFs disrupted compared to the Lu strain ofMYXV
and is missing the M000.5L/R ORF. In comparison, RFV has six
fragmented genes and is missing M000.5L/R, while S023R and
S129R are truncated. Although containing multiple indels, the
disrupted ORFs in MSW can readily be aligned with the ortholo-
gous sequences in Lu. By comparison, RFV has lost substantially
more of its fragmented genes, with relatively little remaining se-
quence in some cases, which is compatible with a longer period of
divergence from the MYXV strains. In addition, RFV contains an
expansion of the TIR boundary compared to Lu, with duplication
of the M156R-S008.2L/R genes and partial duplication of the
S009L gene. The mechanism determining the length of the TIR
region in poxviruses is not understood, but it seems likely that
expansion and contraction of the TIR boundary can occur readily,
and it is difficult to predict which genes the ancestral leporipoxvi-
rus TIRmight have included. A short TIR is compatible with virus
viability; for example, SG33 has a severely truncated TIR due to
deletion of 13.5 kb at the RH end of the genome (22). Similarly,
variola virus, an orthopoxvirus and the causative agent of human
smallpox, carries no genes in its short 725-bp TIRs (44).
Four of the genes missing or truncated in RFV are also missing
or disrupted in MSW: M000.5L/R, M008.1L/R, M152R, and
M023R. This suggests that these genes were either redundant or
selected against in their respective Sylvilagus host species or an
earlier ancestral host. Lu appears to have retained a full comple-
ment of genes compared to the other two leporipoxviruses, with
no obvious fragmented ORFs. Although there are several long
intergenic regions that may once have included ORFs, most of the
genes have very little intervening sequence. The region containing
M000.5L/R in Lu does not align well with that in MSW, and it is
not clear if this potential gene has been lost, was never present and
so may have evolved in South American MYXV, or indeed may
not be a functional gene. All of the disrupted ORFs in MSW con-
tain multiple mutations suggesting that they are nonfunctional.
FIG 4 Bayesian posterior probability support for sliding 100-bp windows between positions 77,000 and 83,000 in themultiple-sequence alignment (Fig. 3). The
blue area indicates support for a grouping of SG33 with Lu and SLS, while the yellow area indicates support for an SG33/MSW grouping, indicative of
microrecombination events.
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MSWhas extreme virulence for European rabbits, based on its
shorter average survival time than that of Lu, minimal clinical
signs, and ability to overcome strong genetic resistance to MYXV
in Australian wild rabbits (11, 12). There are no novel genes that
might explain this high virulence, and two genes that in the Lu
strain are each critical for virulence in European rabbits,
M008.1L/R and M152R, have been lost in MSW. This suggests
either that the duplication of M156R, M154L, M153R, and
M151R—which include two known virulence genes and two likely
immune modulator genes whose effect on virulence has not been
determined—is able to overcome the loss of the M008.1L/R and
M152R genes because of increased expression of the encoded im-
munomodulatory proteins or that sequence differences in other
key proteins are responsible for evenmore efficient suppression of
the European rabbit innate and adaptive immune responses than
that caused by the South American virus. This has presumably
been due to the coevolution with S. bachmani, which has selected
gene variants that suppress the immune response to enable repli-
cation to high titers in localized fibromas. The South American
viruses, however, were unable to reach transmissible titers in S.
bachmani, and the Californian virus did not cause lesions in S.
brasiliensis, even though both viruses are lethal in European rab-
bits (5, 45).
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